Biotech Ethris has teamed up with Thermo Fisher Scientific to provide a fully integrated mRNA platform to the biopharmaceutical market.
This collaboration will bring together Ethris' mRNA technology platforms, with Thermo Fisher's end-to-end, GMP-compliant manufacturing capabilities, facilitating the rapid advancement of mRNA medicines to the clinic.
It will also support the continued optimisation of Ethris' proprietary Stabilised Non-Immunogenic mRNA (SNIM RNA), minimal UTR and mRNA manufacturing technologies, which have already demonstrated positive pharmacodynamic effects, in Phase I topline data of its lead candidate, ETH47.
The locally administrated nasal spray is designed to address the upstream trigger of asthma symptoms, and Phase I data confirms that ETH47 can activate downstream signalling
Given the non-immunogenic nature of SNIM RNAs, they can be administered repeatedly, leading to sustained production of therapeutically active proteins within the human body.
Eligible for multiple routes of administration, the technology can replace or augment missing or non-functional proteins that cause a disease, introduce new proteins to modulate the course of the disease or its symptoms and be used to develop vaccines.
“Thermo Fisher Scientific has a long-standing track record of supporting the development of advanced therapies,” said Dr. Carsten Rudolph, CEO of Ethris.
“By combining our clinically validated mRNA platforms with Thermo Fisher’s manufacturing expertise, we are creating a powerful offering for biopharma partners. This collaboration addresses the increasing demand for scalable, high-quality mRNA technologies and enables us to serve a broader set of collaborators worldwide," she added.
“By partnering with Ethris, we are expanding our services to inlcude mRNA manufacturing, empowering our customers to bring life-changing treatments to patients faster and more efficiently," added Ben Castro, VP and General Manager, Large Molecule, Drug Substance, Thermo Fisher Scientific.
